Hoth Therapeutics Files Dual U.S. Provisional Patents to Expand Oncology Dermatology IP

The filings cover the use of HT-001, a receptor antagonist, for the topical treatment of skin toxicities associated with cancer care.

Hoth Therapeutics Inc. has filed two U.S. provisional patent applications aimed at expanding its oncology pipeline and establishing a new intellectual property platform focused on dermatologic complications arising from modern cancer therapies.

The filings cover the use of HT-001, a receptor antagonist, for the topical treatment of skin toxicities associated with cancer care. According to the company, the first provisional patent focuses on radiation-induced skin toxicity in oncology patients, a common adverse effect of radiotherapy.

The second provisional application addresses dermatologic toxicities linked to emerging targeted cancer therapies, including second and third-generation menin inhibitors.

Together, the applications secure priority intellectual property rights for the use of HT-001 across multiple oncology treatment settings, including radiation therapy and next-generation targeted agents. As cancer therapies continue to extend survival and patients remain on treatment for longer durations, therapy-induced skin toxicities have become a frequent cause of discomfort, reduced quality of life, and, in some cases, treatment interruption.

Radiation-induced dermatitis and skin-related adverse events from targeted cancer therapies are associated with symptoms such as pain, inflammation, severe itching, and increased risk of infection. These complications can lead to dose reductions or discontinuation of cancer treatment. Despite their prevalence, management strategies remain largely supportive, with limited options that directly address the biological mechanisms driving skin injury.

Hoth’s patent applications seek to protect the use of HT-001 to target neurogenic and inflammatory pathways implicated in therapy-induced dermatologic damage. The company has indicated that the compound has a well-established pharmacologic profile and is being evaluated for use in novel therapeutic contexts within oncology supportive care.

“These filings represent a meaningful expansion of our intellectual property estate into an increasingly important area of oncology care,” said Robb Knie, Chief Executive Officer of Hoth Therapeutics, in a statement.

The company noted that the provisional patents provide flexibility to support further preclinical development, formulation work, and the pursuit of additional U.S. and international patent protections. Hoth also stated that the filings could support a broader oncology-adjacent platform with potential relevance across radiation oncology, targeted cancer therapies, and dermatologic conditions linked to inflammation.

Hoth Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for underserved medical needs. The latest filings add to its existing intellectual property portfolio as the company continues to advance multiple development programs.

Stay tuned for more such updates on Digital Health News